CONCLUSIONS: IMPeTUs criteria proved highly reproducible and could therefore be considered as a base for harmonizing PET interpretation in multiple myeloma. A prospective clinical validation of IMPeTUs criteria is underway. 展开 关键词: Multiple myeloma FDG PET/CT Interpretation criteria Standardization ...
multiple myeloma (SMM). These phenotypes lack myeloma-defining events (MDE), such as end-organ damage or amyloidosis. However, patients affected have an abnormally higher rate of monoclonal B cells in their bone marrow (MGUS, SMM) or elevated serum and urinary monoclonal protein that is a clas...
and is not a translocation.doi:10.1111/j.1601-5223.1981.tb01322.xF.B.SHABTAIB.I.B.HALBRECHTB.WileyHereditasShabtai, F., Halbrecht, I (1981) Interpretation of a marker chromosome 17p in multiple myeloma. Hereditas. 95: pp. 11-11...
The long-term consequences of cancer and its therapy on the patients’ immune system years after cancer-free survival remain poorly understood. Here, we present an in-depth characterization of the bone marrow immune ecosystem of multiple myeloma long-ter
Multiple myeloma (MM) is an incurable disease, whose clinical heterogeneity makes its management challenging, highlighting the need for biological features to guide improved therapies. Deregulation of specific long non-coding RNAs (lncRNAs) has been shown in MM, nevertheless, the complete lncRNA transc...
A key element on Multiple Myeloma (MM) evaluation is the quantification of monoclonal proteins. Current techniques include Serum Protein Electrophoresis (SPE), Immunofixation (IFE) and Free Light Chain Assay (FLC, Freelite). All assays are clinically relevant but have some limitations. Especially fo...
Article IgE multiple myeloma: a new case report was published on February 1, 2017 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 55, issue 2).
The results from these studies support further clinical development of zilurgisertib in patients with FOP and patients with anemia due to myelofibrosis, myelodysplastic syndromes, and multiple myeloma.Data availability Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances ...
The long-term effectiveness of immunotherapies against Multiple Myeloma (MM) remains elusive, demonstrated by the inevitable relapse in patients. This underscores the urgent need for an in-depth analysis of the MM tumor-immune microenvironment (TME). Hereto, a representative immunocompetent MM mouse ...
In the MASTER study (NCT03224507), daratumumab+carfilzomib/lenalidomide/dexamethasone (D-KRd) demonstrated promising efficacy in transplant-eligible newly diagnosed multiple myeloma (NDMM). In GRIFFIN (NCT02874742), daratumumab+lenalidomide/bortezomib/de